Tanabe Pharma Corporation: Kidney Diseases trials
The registry lists 11 Kidney Diseases studies with Tanabe Pharma Corporation as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 2Phase 2 6Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)CompletedNCT00501046Phase 3Results posted
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)CompletedNCT00500682Phase 3Results posted
- An Extended Treatment Study of MT-3995 in Patients With Diabetic NephropathyCompletedNCT02676401Phase 2
- Efficacy and Safety of MT-3995 in Patients With Diabetic NephropathyCompletedNCT02517320Phase 2
- Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic NephropathyCompletedNCT02205372Phase 1/2
- Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic NephropathyCompletedNCT01889277Phase 1/2
- Long-term Extension Study of MCI-196TerminatedNCT01814917Phase 3
- Dose-finding Study of MCI-196TerminatedNCT01814904Phase 3
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFRCompletedNCT01756716Phase 2
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With AlbuminuriaCompletedNCT01756703Phase 2
- A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With HyperphosphatemiaTerminatedNCT00451295Phase 3